These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 28724343

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Novel vaccine strategies against emerging viruses.
    García-Sastre A, Mena I.
    Curr Opin Virol; 2013 Apr; 3(2):210-6. PubMed ID: 23477832
    [Abstract] [Full Text] [Related]

  • 4. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
    Hankaniemi MM, Laitinen OH, Stone VM, Sioofy-Khojine A, Määttä JAE, Larsson PG, Marjomäki V, Hyöty H, Flodström-Tullberg M, Hytönen VP.
    Vaccine; 2017 Jun 27; 35(30):3718-3725. PubMed ID: 28579231
    [Abstract] [Full Text] [Related]

  • 5. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.
    Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, Ih-Jen-Su, Sai IH, Liu CC, Chou AH, Lu YJ, Chen CY, Lee PH, Chiang JR, Chong PC.
    Vaccine; 2012 Jan 17; 30(4):703-11. PubMed ID: 22142585
    [Abstract] [Full Text] [Related]

  • 6. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Hernandez LM, Sumathy K, Sahastrabuddhe S, Excler JL, Kochhar S, Smith ER, Gurwith M, Chen RT, Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO, ex-V3SWG).
    Vaccine; 2022 Aug 19; 40(35):5263-5274. PubMed ID: 35715351
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.
    Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN.
    Vaccine; 2011 Nov 21; 29(50):9376-84. PubMed ID: 22001875
    [Abstract] [Full Text] [Related]

  • 8. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges.
    Delrue I, Verzele D, Madder A, Nauwynck HJ.
    Expert Rev Vaccines; 2012 Jun 21; 11(6):695-719. PubMed ID: 22873127
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.
    Li J, Liu G, Liu X, Yang J, Chang J, Zhang W, Yu XF.
    Viruses; 2015 Jul 17; 7(7):3891-909. PubMed ID: 26193302
    [Abstract] [Full Text] [Related]

  • 12. Measles-derived vaccines to prevent emerging viral diseases.
    Frantz PN, Teeravechyan S, Tangy F.
    Microbes Infect; 2018 Jul 17; 20(9-10):493-500. PubMed ID: 29410084
    [Abstract] [Full Text] [Related]

  • 13. [Emerging viral diseases in Europe].
    Löbermann M, Gürtler LG, Eichler-Löbermann B, Reisinger EC.
    Dtsch Med Wochenschr; 2012 Apr 17; 137(17):900-5. PubMed ID: 22511281
    [Abstract] [Full Text] [Related]

  • 14. Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya.
    Gerke C, Frantz PN, Ramsauer K, Tangy F.
    Expert Rev Vaccines; 2019 Apr 17; 18(4):393-403. PubMed ID: 30601074
    [Abstract] [Full Text] [Related]

  • 15. Inactivated and subunit vaccines against porcine reproductive and respiratory syndrome: Current status and future direction.
    Renukaradhya GJ, Meng XJ, Calvert JG, Roof M, Lager KM.
    Vaccine; 2015 Jun 17; 33(27):3065-72. PubMed ID: 25980425
    [Abstract] [Full Text] [Related]

  • 16. An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.
    Wressnigg N, van der Velden MV, Portsmouth D, Draxler W, O'Rourke M, Richmond P, Hall S, McBride WJ, Redfern A, Aaskov J, Barrett PN, Aichinger G.
    Clin Vaccine Immunol; 2015 Mar 17; 22(3):267-73. PubMed ID: 25540268
    [Abstract] [Full Text] [Related]

  • 17. Cell substrates for the production of viral vaccines.
    Aubrit F, Perugi F, Léon A, Guéhenneux F, Champion-Arnaud P, Lahmar M, Schwamborn K.
    Vaccine; 2015 Nov 04; 33(44):5905-12. PubMed ID: 26187258
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vaccinia-based vaccines to biothreat and emerging viruses.
    Nagata LP, Irwin CR, Hu WG, Evans DH.
    Biotechnol Genet Eng Rev; 2018 Apr 04; 34(1):107-121. PubMed ID: 29779454
    [Abstract] [Full Text] [Related]

  • 20. Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.
    Xu Z, Ho M, Bordoloi D, Kudchodkar S, Khoshnejad M, Giron L, Zaidi F, Jeong M, Roberts CC, Park YK, Maslow J, Abdel-Mohsen M, Muthumani K.
    Methods Mol Biol; 2022 Apr 04; 2410():229-263. PubMed ID: 34914050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.